SCHEMBL6528937

SCHEMBL6528937

COc1cccc(CNc2ccc3sc4ccccc4c3c2)c1OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.56
HIF1A Q16665 1/20 0.53
NPC1 O15118 4/20 0.51
RAB9A P51151 3/20 0.51
NPSR1 Q6W5P4 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
LMNA P02545 1/20 0.51
THRB P10828 1/20 0.51
PKM P14618 1/20 0.51
KDM4E B2RXH2 4/20 0.49
ALDH1A1 P00352 4/20 0.49
MAPK1 P28482 3/20 0.49
L3MBTL1 Q9Y468 3/20 0.49
TP53 P04637 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
ALOX15 P16050 1/20 0.49
HTT P42858 1/20 0.49
GAA P10253 4/20 0.49
POLB P06746 3/20 0.49
TSHR P16473 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6485068 0.81 MAPT (0.56) MAPTHIF1ANPC1RAB9ANPSR1
SCHEMBL6526572 0.81 MAPT (0.56) MAPTNPSR1LMNATHRBKDM4E
SCHEMBL6485628 0.79 MAPT (0.56) MAPTHIF1ANPC1RAB9ANPSR1
SCHEMBL6775812 0.78 MAPT (0.43) MAPTLMNAALDH1A1MAPK1GFER
SCHEMBL6770092 0.76 MAPT (0.43) MAPTRAB9ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL6768996 0.76 RAB9A (0.45) MAPTNPC1RAB9ASMN1; SMN2THRB
SCHEMBL6528974 0.76 MAPT (0.55) MAPTNPSR1LMNATHRBPKM
SCHEMBL6526369 0.76 MAPT (0.55) MAPTHIF1ANPC1RAB9ASMN1; SMN2
SCHEMBL6769329 0.75 GAA (0.49) MAPTNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL6528050 0.75 CYP1A2 (0.45) MAPTALDH1A1L3MBTL1GAAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US claimed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US claimed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US claimed
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US disclosed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US disclosed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US disclosed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP disclosed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus HDAC8, ZC3HAV1, ZCCHC8 MAPT 2337/4885HIF1A 3185/4885NPC1 1256/4885
US-20050075332-A1 Tricyclic compounds with antiviral activity HDAC8, CDK8, ZC3HAV1 MAPT 3500/4885HIF1A 1519/4885NPC1 2036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.